Naltrexone, an opioid antagonist, is hypothesized to modulate neurological hyperexcitability in Visual Snow Syndrome by blocking μ-opioid receptors and potentially reducing abnormal cortical neural network activity. When used at low doses, it may help regulate neurotransmitter signaling and potentially ameliorate visual processing abnormalities associated with the syndrome by altering neuronal excitation and inhibition balance.